Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

101. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319b Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table (...) of Contents Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2019 AIM Specialty Health

102. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study

Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study The US guidelines recommend low-dose CT (LDCT) lung cancer screening for high-risk individuals. New solid nodules after baseline screening are common and have a high lung cancer probability. Currently, no evidence exists concerning the risk stratification of non-resolving new solid nodules at first LDCT screening after initial detection.In the Dutch-Belgian Randomized Lung Cancer Screening (NELSON) trial (...) , 7295 participants underwent the second and 6922 participants the third screening round. We included participants with solid nodules that were registered as new or <15 mm³ (study detection limit) at previous screens and received additional screening after initial detection, thereby excluding high-risk nodules according to the NELSON management protocol (nodules ≥500 mm3).Overall, 680 participants with 1020 low-risk and intermediate-risk new solid nodules were included. A total of 562 (55%) new solid

Full Text available with Trip Pro

2019 EvidenceUpdates

103. Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain

Testing behavioral interventions to optimize participation in a population-based colorectal cancer screening program in Catalonia, Spain The aim of the study was to measure the effect of three cost-neutral behavioral interventions on participation compared to the standard invitation letter in a population-based colorectal cancer screening program in 2014. For that purpose, a four-arm randomized field trial was conducted among 5077 individuals aged 50 to 69 years. Over an 8-week period, each (...) week was randomly allocated to the intervention or the control conditions. Individuals assigned to the intervention conditions additionally received a prompt to write down the date to pick up the screening test in a pharmacy. Two of the three intervention groups also included an additional paragraph in the invitation letter on either: 1) the high proportion of individuals participating regularly (social norms condition) or 2) the importance of regular participation (benefit condition). We measured

2019 EvidenceUpdates

104. New screening pathway could help to identify a rare, single-gene form of diabetes

New screening pathway could help to identify a rare, single-gene form of diabetes New screening pathway could help to identify a rare, single-gene form of diabetes Discover Portal Discover Portal New screening pathway could help to identify a rare, single-gene form of diabetes Published on 23 January 2018 doi: A screening pathway using blood and urine tests followed by two genetic (DNA) tests identified all people with a rare subtype of diabetes called monogenic diabetes. The screening pathway (...) study looked at whether a three-step screening process could better identify who should be referred for DNA testing. What did this study do? The UNITED study included 1,418 people in two UK regions diagnosed with diabetes before the age of 30 and currently aged under 50. There were 42 known cases of monogenic diabetes in the sample (previously diagnosed by DNA test). The researchers tested everyone eligible using a three-step diagnostic pathway which included DNA tests for everyone. Firstly

2019 NIHR Dissemination Centre

105. Financial incentives do not increase attendance for diabetic eye screening

Financial incentives do not increase attendance for diabetic eye screening Financial incentives do not increase attendance for diabetic eye screening Discover Portal Discover Portal Financial incentives do not increase attendance for diabetic eye screening Published on 11 July 2017 doi: Two types of financial incentives are not effective at increasing attendance at eye screening for people with diabetes who do not regularly attend screening. Surprisingly, financial incentives may even reduce (...) the numbers of people attending screening. Retinopathy is a type of eye disease common to people with diabetes. Sight deteriorates only in the later stages and early diagnosis and treatment can prevent blindness. Annual eye screening is offered for people with diabetes but take-up could be improved. This trial examined the effectiveness of a small fixed fee incentive and a lottery incentive compared to an invitation letter. Contrary to expectation the financial incentives were worse than the letter

2019 NIHR Dissemination Centre

106. Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation

Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Discover Portal Discover Portal Screen reminders for GPs did not improve anticoagulant prescribing in atrial fibrillation Published on 18 July 2017 doi: General practice software that generated screen reminders for patients with atrial fibrillation did not increase the proportion taking oral anticoagulants (...) it is important to understand why some patients are not taking preventative medicines. This study addressed this challenge by testing software that generated screen reminders when atrial fibrillation patients were seen in general practice. What did this study do? This cluster-randomised controlled trial assigned 47 general practices in England to either usual practice or to a new proprietary software tool – Automated Risk Assessment for Stroke in Atrial Fibrillation. The software generated screen reminders

2019 NIHR Dissemination Centre

107. Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women

Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Discover Portal Discover Portal Self-testing kits for HPV could be a useful option to tackle low cervical screening rates in young women Published on 6 December 2016 doi: Human Papilloma Virus (HPV) self-sampling kits and the opportunity to book appointments had the largest effect (...) in improving cervical screening uptake for those not responding to initial prompts. However, uptake improved only slightly from 27% to 30%, when the kit was sent. A survey of non-attenders showed they value the convenience and privacy of self-testing. This large NIHR trial tested a range of interventions to increase uptake among women eligible for their first cervical screening test. Sending information leaflets or giving online booking options before their first invitation had no effect on uptake within

2019 NIHR Dissemination Centre

108. Intensive management of diabetes detected early at screening shows similar results to standard care

Intensive management of diabetes detected early at screening shows similar results to standard care Intensive management of diabetes detected early at screening shows similar results to standard care Discover Portal Discover Portal Intensive management of diabetes detected early at screening shows similar results to standard care Published on 1 November 2016 doi: Intensive “early” treatment was similar to national guidance-based treatment at preventing diabetes-related complications or heart (...) disease over five years in this large trial. General practices in the UK (49 practices), Netherlands and Denmark screened 135,000 asymptomatic adults aged 40 to 69 for type 2 diabetes before offering one of two treatment approaches. Intensive management was geared towards achieving targets for blood glucose, blood pressure and cholesterol levels by providing support for GPs, and protected time for delivering extra monitoring, healthy lifestyle advice and medication. The comparison group received

2019 NIHR Dissemination Centre

109. Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources

Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources Abdominal aortic aneurysm screening for women not cost effective Discover Portal Discover Portal Abdominal aortic aneurysm screening for women is unlikely to be a fair use of NHS resources Published on 13 November 2018 doi: Nearly 4,000 women would need screening to prevent one death, and a third of aneurysms detected wouldn’t have influenced the individual woman's health or lifespan. Aneurysm rupture (...) is a life-threatening emergency with low survival. Men are known to be at higher risk of an aneurysm and are offered screening at age 65 to allow early diagnosis of aneurysms large enough to warrant surgical repair. However, a third of deaths from rupture are in women. This NIHR-funded study is the first to model the potential benefits, harms and cost-effectiveness of abdominal aortic aneurysm screening in women. All screening scenarios were estimated to exceed the NHS cost-effectiveness threshold

2019 NIHR Dissemination Centre

110. Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. (PubMed)

Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. In 2016, universal individual donation nucleic acid testing (ID-NAT) of donated blood for Zika virus began in U.S. states and territories.To assess the cost-effectiveness of universal ID-NAT in the first year of screening compared with alternatives for the 50 states and separately for Puerto Rico.Microsimulation that captured Zika-related harms to transfusion recipients, sexual (...) Puerto Rico, MP-NAT exclusively during high mosquito season was cost-effective at $81 123 per QALY (95% CI, -$49 138 to $978 242 per QALY). No screening policy was cost-effective in the 50 states. Universal ID-NAT cost $341 million per QALY (CI, $125 million to $2.90 billion per QALY) compared with no screening in the 50 states.In Puerto Rico, MP-NAT only during the season of high mosquito activity was most cost-effective in 64% of probabilistic sensitivity analysis iterations. In the 50 states

2019 Annals of Internal Medicine

111. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm (...) with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could

2019 EvidenceUpdates

112. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA www.ecdc.europa.euECDC SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA ii This report from the European Centre for Disease Prevention and Control (ECDC (...) Prevention and Control. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA. Stockholm: ECDC; 2018. Stockholm, November 2018 ISBN 978-92-9498-280-3 doi: 10.2900/154411 Catalogue number TQ-04-18-919-EN-N © European Centre for Disease Prevention and Control, 2018 Reproduction is authorised, provided the source is acknowledged. SCIENTIFIC ADVICE Public health guidance on screening and vaccination for infectious diseases in newly arrived

2019 European Centre for Disease Prevention and Control - Public Health Guidance

113. Avioq htlv-i/ii microelisa system - for use in screening individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II, and for use as an aid in clinical diagnosis

Avioq htlv-i/ii microelisa system - for use in screening individual human donors, including volunteer donors of whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II, and for use as an aid in clinical diagnosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2019 Health Canada - Drug and Health Product Register

114. A systematic review to determine the rate of sudden cardiac arrest and death in athletes, and to determine the benefits and harms of the electrocardiogram screening of athletes

A systematic review to determine the rate of sudden cardiac arrest and death in athletes, and to determine the benefits and harms of the electrocardiogram screening of athletes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability (...) : Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review

2019 PROSPERO

115. A systematic review of cervical cancer screening preferences among vulnerable women in developed countries

A systematic review of cervical cancer screening preferences among vulnerable women in developed countries Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening

2019 PROSPERO

116. A systematic review exploring the patient decision-making factors and attitudes towards pre-implantation genetic screening for medical and non-medical reasons

A systematic review exploring the patient decision-making factors and attitudes towards pre-implantation genetic screening for medical and non-medical reasons Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) : Exclusion criteria: Example: Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2

2019 PROSPERO

117. Barriers and facilitators to uptake of flexible sigmoidoscopy screening for CRC detection

Barriers and facilitators to uptake of flexible sigmoidoscopy screening for CRC detection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites (...) . Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed

2019 PROSPERO

118. Associations between infant bilirubin and neonatal screening biomarkers: a systematic review protocol

Associations between infant bilirubin and neonatal screening biomarkers: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening

2019 PROSPERO

119. Assessment tools used to screen for dementia in African adults in hospital and community settings, a mixed methods review

Assessment tools used to screen for dementia in African adults in hospital and community settings, a mixed methods review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) : Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2019 PROSPERO

120. Circulating cell-free fetal DNA for the prenatal screening of copy number variants: a systematic review and meta-analysis

Circulating cell-free fetal DNA for the prenatal screening of copy number variants: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) : Screening will be performed in two phases, namely initial screening based on title and abstract, followed by full-text screening of the eligible articles for final inclusion. In each phase, 2 observers will independently assess each article. Discrepancies will be resolved through discussion, or by consulting a third investigator. ">Procedure for study selection Example : Title-abstract screening: 1. Not an original full research paper (e.g. review, editorial) 2. Not an in vivo animal study 3

2019 PROSPERO